Takeda Pharmaceutical - TAK Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.00
  • Forecasted Upside: 61.94 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$14.82
▼ -0.05 (-0.34%)

This chart shows the closing price for TAK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Takeda Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TAK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TAK

Analyst Price Target is $24.00
▲ +61.94% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Takeda Pharmaceutical in the last 3 months. The average price target is $24.00, with a high forecast of $24.00 and a low forecast of $24.00. The average price target represents a 61.94% upside from the last price of $14.82.

This chart shows the closing price for TAK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Takeda Pharmaceutical. This rating has held steady since October 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/29/2022Jefferies Financial GroupDowngradeBuy ➝ HoldLow
7/19/2022CowenUpgradeMarket Perform ➝ Outperform$21.00 ➝ $24.00Low
7/19/2022CowenUpgradeMarket Perform ➝ OutperformLow
1/13/2022The Goldman Sachs GroupDowngradeBuy ➝ NeutralLow
10/29/2021Jefferies Financial GroupUpgradeHold ➝ BuyLow
10/6/2021Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
4/19/2021JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
4/5/2021Jefferies Financial GroupDowngradeBuy ➝ HoldLow
3/11/2020JPMorgan Chase & Co.Lower TargetOverweight$31.00 ➝ $30.00Low
11/1/2019CowenInitiated CoverageMarket Perform$19.50High
9/24/2019Jefferies Financial GroupInitiated CoverageBuyLow
8/15/2019Daiwa Capital MarketsDowngradeOutperform ➝ NeutralLow
3/19/2019The Goldman Sachs GroupReiterated RatingBuyMedium
(Data available from 12/4/2017 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/8/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/7/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/7/2022
  • 7 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/6/2022
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/5/2022
  • 9 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/5/2022
  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/4/2022
  • 8 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 8 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Takeda Pharmaceutical logo
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $14.82
Low: $14.61
High: $14.82

50 Day Range

MA: $13.42
Low: $12.42
High: $14.87

52 Week Range

Now: $14.82
Low: $12.28
High: $15.36

Volume

1,637,936 shs

Average Volume

2,234,782 shs

Market Capitalization

$45.95 billion

P/E Ratio

27.44

Dividend Yield

1.86%

Beta

0.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Takeda Pharmaceutical?

The following Wall Street analysts have issued reports on Takeda Pharmaceutical in the last year: Cowen Inc, Cowen Inc., Jefferies Financial Group Inc., and The Goldman Sachs Group, Inc..
View the latest analyst ratings for TAK.

What is the current price target for Takeda Pharmaceutical?

1 Wall Street analysts have set twelve-month price targets for Takeda Pharmaceutical in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 61.9%. Cowen Inc. has the highest price target set, predicting TAK will reach $24.00 in the next twelve months. Cowen Inc. has the lowest price target set, forecasting a price of $24.00 for Takeda Pharmaceutical in the next year.
View the latest price targets for TAK.

What is the current consensus analyst rating for Takeda Pharmaceutical?

Takeda Pharmaceutical currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TAK will outperform the market and that investors should add to their positions of Takeda Pharmaceutical.
View the latest ratings for TAK.

What other companies compete with Takeda Pharmaceutical?

How do I contact Takeda Pharmaceutical's investor relations team?

Takeda Pharmaceutical's physical mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company's listed phone number is (166) 204-2111. The official website for Takeda Pharmaceutical is www.takeda.com. Learn More about contacing Takeda Pharmaceutical investor relations.